Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort -

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
Long-term follow up results from a primary analysis of the NOAH trial suggest sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in locally advanced or inflammatory breast cancer (median follow up 5.4 years).
UKMi comment

The following resource may also be of interest:
Related links: Comment full text – access to subscribers only